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CASE HISTORY
A 39-year-old female was admitted for antibiotic treat-
ment of sepsis of unknown origin, which had been
empirically treated with piperacillin-tazobactam. The
patient had previously (five months prior) been diagnosed
with renal cell carcinoma with clear cell histological features
and had undergone a left partial nephrectomy without
excision of the entire tumor. Three months before admis-
sion, the patient was recruited to participate in a clinical trial
investigating hepatic and pancreatic metastasis; the partici-
pants received interferon and bevacizumab in one of the
protocols. The patient did not present any indication of
pulmonary involvement from cancer in a tomography scan
taken one month before admission.
During her hospital stay, the patient presented a sudden
onset of shortness of breath, tachypnea, and chest discomfort
without hemodynamic repercussion. On physical examina-
tion, the patient exhibited decreased breath sounds in her left
hemithorax and tympanic percussion. Trachea deviation was
also observed to the right and the patient presented with
bilateral jugular stasis. Her saturation was 91% despite
oxygen given at a 10-l/min rate through an oxygen mask.
A thoracocentesis with air escape in the second intercostal
space was immediately performed by the thoracic surgeon. A
left-sided hydropneumothorax was diagnosed in the chest
roentgenogramwithcontralateralmediastinalshift(Figure1).
The patient was transferred to the intensive care unit (ICU)
with chest discomfort despite drainage with a chest drain. A
small amount of odorless, turbid brownish fluid came from
the pleural space just after the drainage.
After non-invasive mechanical ventilation, the chest
discomfort progressively improved, and both lungs were
expanded. Upon discharge from the ICU, a liquid resem-
bling nasogastric feed started to emerge from the chest drain
in increasing amounts and shortly after commencing
feeding with an output of more than 2300 ml per day.
Biochemical analysis of the pleural effusion revealed a
neutrophilic exudate with a low pH (6.32), low protein
(1.5 g/dl), normal glucose (103 mg/dl), and high levels of
lactate dehydrogenase (DHL) and amylase (16864 U/l and
873 U/l, respectively). The level of serum amylase was
23 U/l. The cytological exam was inconclusive. Because of
the high levels of amylase, an esophageal perforation was
initially suspected. A methylene blue test was performed at
the bedside with a positive result, indicating leakage of this
substance in the chest drain insertion after oral administra-
tion. Computed tomography with oral contrasted medium
through the feeding tube showed a gastropleural fistula
originating from the greater curvature and extending to the
left subphrenic space (Figure 2). The patient was submitted
to parenteral nutrition.
Two days after the diagnosis, the patient presented
sudden bleeding exteriorized by the chest tube (approxi-
mately 1800 ml of sanguineous pleural effusion) and
hypovolemic shock. The patient was transferred again to
the ICU where the patient received fluid, blood, and
vasopressor support and recovered from the shock. Upper
gastrointestinal endoscopy revealed a large blood clot in the
greater curvature and fundus, which impeded further
exploration. The patient was submitted to embolization of
the splenic arteries in the interventional radiology service
with success, and no further bleeding episodes occurred.
After discussion with the Gastro Surgery team and
considering the surgical risk due to the patient’s poor
status, the patient was transferred to a palliative care
facility. The patient died ten days after the embolization,
due to shock and acute respiratory insufficiency.
DISCUSSION
Gastropleural fistula is an uncommon diagnosis. It has
been previously reported as a complication after pulmonary
resections,
1 trauma (especially due to traumatic diaphrag-
matic hernia), complications of peptic ulcer disease, and
malignancy.
2 Some case reports have indicated a predis-
position caused by oral steroids or anti-inflammatory drug
intake when the cause is gastric perforation.
3 According to a
recent literature review,
4 subphrenic pathologies less
frequently lead to this condition, generally due to diaphrag-
matic erosion. Supradiaphragmatic conditions, such as
infections, intrathoracic surgeries, and fistulas due to
procedures (caused by forceful intercostal tube insertion
4
and after nasogastric tube placement after gastric adeno-
carcinoma resection)
5 can also result in this condition.
Gastric ulcers have been described as the most frequent
cause of gastropleural fistulas. With the advent of intensive
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1495treatment regimens involving proton pump inhibitors and
eradication therapy for Helicobacter pylori infection, one
would expect that the incidence of gastropleural fistulas
would decrease.
6 Unfortunately, gastropleural fistulas can
also occur secondarily to intra-abdominal or thoracic
malignancies, which occur increasingly frequently with
aging. Published case reports include a B-cell lymphoma
7
and two gastric mucosa-associated lymphoid tissue (MALT)
lymphomas.
6,8
To our knowledge, this is the first reported case of
gastropleural fistula caused by gastric perforation due to
renal cell carcinoma invasion. Bevacizumab is a recombinant,
humanized monoclonal antibody that binds to vascular
endothelial growth factor (VEGF) and inhibits angiogenesis.
VEGF is a survival factor for blood vessels in certain types of
tumors. Inhibition of VEGF signaling in tumors results in the
cessation of angiogenesis, regression of some tumor vessels,
normalization of others, and improved drug delivery. Unlike
the blood vessels in tumors, the normal vasculature in adults
is considered to be stable and, therefore, largely independent
of VEGF for survival. However, VEGF and VEGF receptors
are still highly expressed in several adult organs, and
endothelial fenestrations can be induced by VEGF inhibitors
in vitro and in vivo.
9 The inhibition of VEGF signaling can
eliminate fenestrations in tumor vessels, leading to impaired
wound repair and predisposing the patient to fistula
formation and bleeding. This potent anti-neoplastic agent
has recently been reported to be associated with an increased
risk of wound suture dehiscence requiring intervention,
fistulas, gastrointestinal perforation, and serious bleeding/
hemorrhage.
10 Among the nongastrointestinal fistulas, tra-
cheoesophageal, bronchopleural, biliary, vaginal, renal, and
bladder fistulas have been observed, most commonly within
the first six months of treatment.
11 No cases of gastropleural
fistulas have been reported.
The diagnosis of gastropleural fistula is usually deter-
mined by contrast radiology,
12 upper gastrointestinal endo-
scopy, and pleural fluid testing. In the present case, the
cytological exam was not helpful, due to cellular lysis.
Although conservative management has been suggested
in a recent review of enteral fistulas after bevacizumab
chemotherapy,
11 this approach is often unsuccessful in
patients with gastropleural fistulas, making surgery man-
datory. Unfortunately, the potential bleeding caused by
bevacizumab would impose unacceptable risks to this
patient if surgery was attempted.
In conclusion, although gastropleural fistulas are rela-
tively uncommon, the condition requires prompt surgical
intervention. Although its incidence due to gastric perfora-
tions is low, subdiaphragmatic and intrathoracic tumors
will increase the likelihood of this complication. New
chemotherapeutic agents, such as bevacizumab, can pro-
mote fistulas caused by tumor necrosis, and gastropleural
fistulas should be considered as a possible complication.
Figure 2 - Coronal computed tomography reconstruction with oral contrasted medium through the feeding tube. A heterogeneous solid
mass with extensive necrotic areas in the left renal space invades the posterior wall of the stomach. The gastropleural fistula originates
from the greater curvature extending to the left subfrenic space. Bilateral pleural effusion and partial athelectasis from the left lower
lobe with air bronchograms are observed. Other small hipoattenuating hepatic lesions can also be seen due to hepatic metastasis.
Figure 1 - Chest roentgenogram showing left-sided tension
hydropneumothorax with contralateral mediastinal shift.
Gastropleural fistula
Dias OM et al.
CLINICS 2011;66(8):1495-1497
1496REFERENCES
1. Takeda S, Funaki S, Yumiba T, Ohno K. Gastropleural fistula due to
gastric perforation after lobectomy for lung cancer. Interact CardioVasc
Thorac Surg. 2005;4:420-2, doi: 10.1510/icvts.2005.108779.
2. Schwab RJ, Jarvik JG. Tension pneumothorax secondary to a gastro-
pleural fistula in a traumatic diaphragmatic hernia. Chest. 1991;99:247-9,
doi: 10.1378/chest.99.1.247.
3. Keefe P, Goldstraw P. Gastropleural fistula following pulmonary
resection. Thorax. 1993;48:1278-9, doi: 10.1136/thx.48.12.1278.
4. Darbari A, Tandon S, Singh GP. Gastropleural fistula: rare entity with
unusual etiology. Ann Thorac Med. 2007;2:64-5, doi: 10.4103/1817-1737.
32233.
5. Bini A, Grazia M, Petrella F, Stella F, Bazzocchi R. Spontaneous
biliopneumothorax (Thoracobilia) following gastropleural fistula due to
stomachperforation bynasogastric tube. AnnThoracSurg.2004;78:339-41,
doi: 10.1016/S0003-4975(03)01282-7.
6. Adachi Y, Sato Y, Yasui H, Nishimura S, Tanimura A, Yuasa H, et al.
Gastropleural fistula derived from malignant lymphoma. J Gastroenterol.
2002;37:1052-6, doi: 10.1007/s005350200177.
7. Mehran A, Ukleja A, Szomstein S, Rosenthal R. Laparoscopic partial
gastrectomy for the treatment of gastropleural fistula. JSLS. 2005;9:213-5.
8. Warburton CJ, Calverly PM. Gastropleural fistula due to gastric
lymphoma presenting as tension pneumothorax and empyema. Eur
Resp J. 1997;10:1678-9, doi: 10.1183/09031936.97.10071678.
9. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR,
et al. VEGF-dependent plasticity of fenestrated capillaries in the normal
adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:
560-76, doi: 10.1152/ajpheart.00133.2005.
10. Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N,
et al. Tracheoesophageal fistula formation in patients with lung cancer
treated with chemoradiation and bevacizumab. J Clin Oncol. 2010;28:43-
8, doi: 10.1200/JCO.2009.24.7353.
11. Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, EllisLM et al. Management
of bevacizumab-associated bowel perforation: a case series and review of the
literature. Ann Oncol. 2008;19:577-82, doi: 10.1093/annonc/mdm508.
12. Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV. Tumor
fistulization associated with targeted therapy: computed tomographic
findings and clinical consequences. J Comput Assist Tomogr. 2011;35:
86-90, doi: 10.1097/RCT.0b013e3181fce2cb.
CLINICS 2011;66(8):1495-1497 Gastropleural fistula
Dias OM et al.
1497